Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,643 shares of the biopharmaceutical company’s stock after selling 1,753 shares during the period. Fifth Third Bancorp’s holdings in Regeneron Pharmaceuticals were worth $6,157,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. International Assets Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. Icon Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after buying an additional 75,569 shares during the period. State Street Corp raised its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in Regeneron Pharmaceuticals by 40.2% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock valued at $204,598,000 after acquiring an additional 55,828 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on REGN. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $675.79 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The firm has a market capitalization of $74.26 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business has a 50 day simple moving average of $727.19 and a 200-day simple moving average of $936.96.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.